Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia: Drugs and pharmacology

Journal of the American Geriatrics Society

Volumn 57, Issue 3, 2009, Pages 536-546

  Molnar, Frank J ^a,b,c,e   Man Son Hing, Malcolm ^a,b,c   Fergusson, Dean ^a,b,d  

^a Clinical Epidemiology Program   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c BRUYÈRE RESEARCH INSTITUTE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Alzheimer's; Clinical importance; Dementia; Significance

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE; MEMANTINE; PLACEBO;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; DEMENTIA; DRUG RESEARCH; HUMAN; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW;

AGED; ALZHEIMER DISEASE; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; HUMANS; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 61449091559     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2008.02122.x     Document Type: Article

References (50)

1. Ferri CP, Prince M, Brayne C et al. Global prevalence of dementia: A Delphi consensus study. Lancet 2005 366 : 2112 2117.
2. Wimo A, Winblad B, Sto″ffler A et al. Resource utilization and cost analysis of Memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003 21 : 327 340.
3. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: Ascertaining the minimal clinically important difference. Controlled Clin Trials 1989 10 : 407 415.
4. Naylor CD, Llewellyn-Thomas HA. Can there be a more patient-centered approach to determining clinically important effect sizes for randomized treatment trials? J Clin Epidemiol 1994 47 : 787 795.
5. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: A comparison of two techniques. J Clin Epidemiol 1996 49 : 1215 1219.
6. Jacobson NS, Roberts LJ, Berns SB et al. Methods for defining and determining the clinical significance of treatment effects: Description, application, and alternatives. J Consult Clin Psychol 1999 67 : 300 307.
7. Man-Son-Hing M, Laupacis A, O'Rourke K et al. Determination of the clinical importance of study results: A review. J Gen Intern Med 2002 17 : 469 476.
8. Burback D, Molnar FJ, St John P et al. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Dement Geriatr Cogn Disord 1999 10 : 534 540.
9. Chan KBY, Man-Son-Hing M, Molnar FJ et al. How well is clinical importance of study results reported? An assessment of randomized controlled trials. Can Med Assoc J 2001 165 : 1197 1202.
10. Van Walraven C, Mahon JL, Moher D et al. Surveying physicians to determine the minimal important difference: Implications for sample-size calculation. J Clin Epidemiol 1999 52 : 717 723.
11. Burnand B, Kernant WN, Feinstein AR. Indexes and Boundaries for 'quantitative significance' in statistical decisions. J Clin Epidemiol 1990 43 : 1273 1284.
12. Wells GA, Tugwell P, Kraag GR et al. Minimum important difference between patients with rheumatoid arthritis: The patients perspective. J Rheumatol 1993 20 : 557 560.
13. Clarke M. The QUORUM statement. Lancet 2000 355 : 756 757.
14. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. Washington, DC : American Psychiatric Association, 2000.
15. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 34 : 939 944.
16. Roman GC, Tatemichi TK, Erkinjuntti T et al. Vascular dementia; diagnostic criteria for research studies: Report of the NINDS-AIREN international Workshop. Neurology 1993 43 : 250 260.
17. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996 17 : 1 12.
18. Rogers SL, Doody RS, Mohs RC et al. Donepezil improves cognition and global function in Alzheimer disease: A 15 week, double-blind, placebo-controlled study. Arch Intern Med 1998 158 : 1021 1031.
19. Rogers SL, Farlow MR, Doody RS. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998 50 : 136 145.
20. Corey-Bloom J, Anand R, Veach J et al. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1998 1 : 55 65.
21. Rösler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomized controlled trial. BMJ 1999 318 : 633 640.
22. Winblad B, Poritis N. Memantine in severe dementia: Results of the 9M-BEST study (Benefit and efficacy in severely demented patients during treatment with Memantine). Int J Geriatr Psychiatry 1999 14 : 135 146.
23. Homma A, Takeda M, Imai Y et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2000 11 : 299 313.
24. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomized controlled trial. BMJ 2000 321 : 1 7.
25. Feldman H, Guathier S, Hecker J et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001 57 : 613 620.
26. Mohs RC, Doody RS, Morris JC et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001 57 : 481 488.
27. Tariot PN, Cummings JL, Katz IR et al. A randomized, Double-blind, Placebo-controlled study of the efficacy and safety of Donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001 49 : 1590 1599.
28. Winblad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001 57 : 489 495.
29. Rockwood K, Mintzer J, Truyen L et al. Effects of a flexible galantamine dose in Alzheimer's disease: A randomised, controlled trial. J Neurol Neurosurg Psychaitry 2001 71 : 589 595.
30. Wilkinson D, Murray J. The Galantamine Research group. Galantamine: A randomised, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001 16 : 852 857.
31. Orgogozo J-M, Rigaud A-S, Stöffler A et al. Efficacy and safety of Memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300). Stroke 2002 33 : 1834 1839.
32. Reisberg B, Doody R, Stöffler A et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003 348 : 1333 1341.
33. Black S, RomÜn GC, Geldmacher DS et al. Efficacy and tolerability of donepezil in vascular dementia: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003 34 : 2323 2332.
34. AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. Lancet 2004 363 : 2105 2115.
35. Karaman Y, Erdoǧan F, Ko″seoǧlu E et al. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005 19 : 51 56.
36. Johannsen P, Salmon E, Hampel H et al. Assessing therapeutic efficacy in a progressive disease: A study of Donepezil in Alzheimer's disease. CNS Drugs 2006 20 : 311 325.
37. Winblad B, Kilander L, Eriksson S et al. Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study. Lancet 2006 367 : 1057 1065.
38. Rockwood K, Fay S, Song X et al. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: A randomised controlled trial. Can Med Assoc J 2006 174 : 1099 1105.
39. Peskind ER, Potkin SG, Pomara N et al. Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006 14 : 704 715.
40. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: Results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis 2007 11 : 471 479.
41. Black SE, Doody R, Li H et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007 69 : 459 469.
42. Feldman HH, Lane R the Study 304 group. Rivastigmine: A placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007 78 : 1056 1063.
43. Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomised, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007 22 : 456 467.
44. Reisberg B, Schneider L, Doody R et al. Clinical global measures of dementia: Position paper from the International Working Group on Harmonization of dementia Drug Guidelines. Alzheimer Dis Ass Disord 1997 11 (Suppl 3) : 8 18.
45. Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol neurosurg Psychiatry 2004 75 : 677 685.
46. Livingston G, Katona C. The place of memantine in the treatment of Alzheimer's disease: A number needed to treat analysis. Int J Geriatr Psychiatry 2004 19 : 919 925.
47. Kendall PC, Marrs-Garcia A, Nath SR et al. Normative comparisons for the evaluation of clinical significance. J Consult Clin Psychol 1999 67 : 285 299.
48. Food and Drug Administration. Peripheral and Central Nervous System Drugs Advisory Committee Meeting. Rockville, MD : Department of Health and Human Services, Public health Service, 1989. 227.
49. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004 351 : 2509 2518.
50. McLendon BM, Doraiswamy PM. Defining meaningful change in Alzheimer's disease trials: The donepezil experience. J Geriatr Psychiatry Neurol 1999 12 : 39 48.